{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:53:18Z","timestamp":1791395598278,"version":"4.3.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Both the elderly and individuals with comorbidities are at increased risk of developing influenza-related complications. Novel influenza antivirals are required, given limitations of current drugs (eg, resistance emergence and poor efficacy). Pimodivir is a first-in-class antiviral for influenza A under development for these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Hospitalized patients with influenza A infection were randomized 2:1 to receive pimodivir 600 mg plus oseltamivir 75 mg or placebo plus oseltamivir 75 mg twice daily for 7 days in this phase 2b study. The primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65\u201385 years) versus nonelderly adults (aged 18\u201364 years). Secondary end points included time to patient-reported symptom resolution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pimodivir pharmacokinetic parameters in nonelderly and elderly patients were similar. Time to influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours). There was a lower incidence of influenza-related complications in the pimodivir group (7.9%) versus placebo group (15.6%). Treatment was generally well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No apparent relationship was observed between pimodivir pharmacokinetics and age. Our data demonstrate the need for a larger study of pimodivir in addition to oseltamivir to test whether it results in a clinically significant decrease in time-to-influenza-symptom alleviation and\/or the frequency of influenza complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trials registration<\/jats:title>\n                  <jats:p>NCT02532283.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa376","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T19:23:59Z","timestamp":1593113039000},"page":"109-118","source":"Crossref","is-referenced-by-count":30,"title":["A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study"],"prefix":"10.1093","volume":"226","author":[{"given":"Brian","family":"O\u2019Neil","sequence":"first","affiliation":[{"name":"Wayne State University School of Medicine, Detroit Medical Center , Detroit, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-9671","authenticated-orcid":false,"given":"Michael G","family":"Ison","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Charlotte","family":"Hallouin-Bernard","sequence":"additional","affiliation":[{"name":"University Hospital of Tours , Tours , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Unit, Department of Translational Medicine, Sk\u00e5ne University Hospital , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[{"name":"Servei de Pneumologia Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, Biomedical Research Networking Center on Respiratory Diseases, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Wilburn","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine, Detroit Medical Center , Detroit, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert","family":"van Duijnhoven","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Van Dromme","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Anderson","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, LLC , Titusville, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Deleu","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teddy","family":"Kosoglou","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, LLC , Titusville, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vingerhoets","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"Rossenu","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorant","family":"Leopold","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, LLC , Titusville, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"2022081210480960200_jiaa376-CIT0001","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","article-title":"Influenza virus evolution, host adaptation, and pandemic formation","volume":"7","author":"Taubenberger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"2022081210480960200_jiaa376-CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6703a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018\u201319 Influenza Season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"2022081210480960200_jiaa376-CIT0003","doi-asserted-by":"crossref","first-page":"f5061","DOI":"10.1136\/bmj.f5061","article-title":"Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis","volume":"347","author":"Mertz","year":"2013","journal-title":"BMJ"},{"key":"2022081210480960200_jiaa376-CIT0004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.15585\/mmwr.mm6706a1","article-title":"Update: influenza activity - United States, October 1, 2017-February 3, 2018","volume":"67","author":"Budd","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022081210480960200_jiaa376-CIT0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/irv.12550","article-title":"Heterogeneous estimates of influenza virus types A and B in the elderly: results of a meta-regression analysis","volume":"12","author":"Panatto","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"2022081210480960200_jiaa376-CIT0006","doi-asserted-by":"crossref","first-page":"430629","DOI":"10.1155\/2014\/430629","article-title":"A review of the antiviral susceptibility of human and avian influenza viruses over the last decade","volume":"2014","author":"Oh","year":"2014","journal-title":"Scientifica"},{"key":"2022081210480960200_jiaa376-CIT0007","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2022081210480960200_jiaa376-CIT0008","article-title":"XOFLUZA prescribing information","author":"Genentech","year":"2018"},{"key":"2022081210480960200_jiaa376-CIT0009","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1093\/cid\/ciu632","article-title":"Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients","volume":"59","author":"de Jong","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022081210480960200_jiaa376-CIT0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","article-title":"Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial","volume":"5","author":"Marty","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2022081210480960200_jiaa376-CIT0011","article-title":"Influenza antiviral medications: summary for clinicians","author":"Centers for Disease Control and Prevention"},{"key":"2022081210480960200_jiaa376-CIT0012","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"2022081210480960200_jiaa376-CIT0013","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","volume":"219","author":"Finberg","year":"2019","journal-title":"J Infect Dis"},{"key":"2022081210480960200_jiaa376-CIT0014","article-title":"\u2014summary of product characteristics"},{"key":"2022081210480960200_jiaa376-CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-015-1330-0","article-title":"Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza","volume":"16","author":"Powers","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2022081210480960200_jiaa376-CIT0016","article-title":"Medical Dictionary for Regulatory Activities, Version 19.1","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"key":"2022081210480960200_jiaa376-CIT0017","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jval.2010.12.005","article-title":"Development and validation of the influenza intensity and impact questionnaire (FluiiQ\u2122)","volume":"14","author":"Osborne","year":"2011","journal-title":"Value Health"},{"key":"2022081210480960200_jiaa376-CIT0018","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin pilot study (INSIGHT 005: Flu-IVIG Pilot)","author":"National Institute of Allergy and Infectious Diseases"},{"key":"2022081210480960200_jiaa376-CIT0019","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/bcp.13733","article-title":"Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a phase 1 open-label study in healthy volunteers","volume":"84","author":"Deleu","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2022081210480960200_jiaa376-CIT0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1086\/600384","article-title":"Influenza in hospitalized adults: gaining insight into a significant problem","volume":"200","author":"Ison","year":"2009","journal-title":"J Infect Dis"},{"key":"2022081210480960200_jiaa376-CIT0021","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2014.11.020","article-title":"Neuraminidase inhibitors: who, when, where?","volume":"21","author":"Nguyen-Van-Tam","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2022081210480960200_jiaa376-CIT0022","doi-asserted-by":"crossref","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill"},{"key":"2022081210480960200_jiaa376-CIT0023","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/1740774517697919","article-title":"Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization","volume":"14","author":"Peterson","year":"2017","journal-title":"Clin Trials"},{"key":"2022081210480960200_jiaa376-CIT0024","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"key":"2022081210480960200_jiaa376-CIT0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.apsb.2015.07.006","article-title":"New small-molecule drug design strategies for fighting resistant influenza A","volume":"5","author":"Shen","year":"2015","journal-title":"Acta Pharm Sin B"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa376\/33525678\/jiaa376.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/1\/109\/45379029\/jiaa376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/1\/109\/45379029\/jiaa376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T10:58:46Z","timestamp":1660301926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/1\/109\/5865447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,7,1]]},"published-print":{"date-parts":[[2022,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa376","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2020,7,1]]}}}